Jordi Remon: Unresolved challenges with ICB and TKIs for early stage NSCLC

Jordi Remon, a Thoracic oncologist at CIOCC Barcelona, recently posted on X:

“In the current landscape treatments for early stage NSCLC several challenges with immunotherapy (ICB) and TKIs remain unresolved.We describe current data and challenges in this setting: role ICB in stage II or PDL1<1%,adjuvant TKI for all?.

Thanks to all authors!”

Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies

Autors: Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, David O’Reilly, Jarushka Naidoo, Giannis Mountzios, Olaf Mercier, Lizza E. L. Hendriks, Jordi Remon

Source: Jordi Remon/X